Very low C-reactive protein in apparently healthy individuals: physiological status or just a reflection of an improved health profile

References

• Ben-Assayag E, Shenhar-Tsarfaty S, Bova I, Berliner S, Shopin L, Peretz H, Usher S, Shapira I, Bornstein NM. Triggered C-reactive protein (CRP) concentrations and the CRP gene -717A > G polymorphism in acute stroke or transient ischemic attack. European Journal of Neurology 2007; 14: 315–320
   PubMedGoogle Scholar
• Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematologica Basel 1957; 17: 237–246
   PubMedGoogle Scholar
• Fujii H, Li SH, Szmitko PE, Fedak PW, Verma S. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arteriosclerosis Thrombosis Vascular Biology 2006; 26: 2476–2482
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005; 127: 558–564
   PubMed Web of Science ®Google Scholar
• Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA: The Journal of the American Medical Association 2003; 290: 932–940
   PubMed Web of Science ®Google Scholar
• Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001; 357: 763–767
   PubMed Web of Science ®Google Scholar
• International Committee for Standardization in Hematology. 1965. Recommendation of measurement of erythrocyte sedimentation rate of human blood. Immunochemistry 2:235–254.
   PubMedGoogle Scholar
• Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney JF, Jr, Wilson PW, Newton-Cheh C, Musone SL, Camargo AL, Drake JA, Levy D, O'Donnell CJ, Hirschhorn JN, Benjamin EJ. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415–1423
   PubMed Web of Science ®Google Scholar
• Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify?. American Journal of Medicine 2006; 119: 166.e17–166.e28
   Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). The Journal of the American Medical Association 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217–1221
   PubMed Web of Science ®Google Scholar
• Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation 2002; 105: 2–4
   PubMed Web of Science ®Google Scholar
• Ridker PM. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003; 108: e81–e85
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391–397
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Burning JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine 2002; 347: 1557–1565
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955–1959
   PubMed Web of Science ®Google Scholar
• Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry 1999; 45: 2136–2141
   PubMed Web of Science ®Google Scholar
• Rogowski O, Zeltser D, Shapira I, Burke M, Zakuth V, Mardi T, Ben-asayag E, Serov J, Rozenblat M, Berliner S. Gender difference in C-reactive protein concentrations in individuals with atherothrombotic risk factors and apparently healthy ones. Biomarkers 2004; 9: 85–92
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA: The Journal of the American Medical Association 2003; 290: 2945–2951
   PubMed Web of Science ®Google Scholar
• Singh U, Devaraj S, Dasu MR, Ciobanu D, Reusch J, Jialal I. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arteriosclerosis Thrombosis and Vascular Biology 2006; 26: 2469–2475
   PubMedGoogle Scholar
• Tomaszewski M, Charchar FJ, Przybycin M, Crawford L, Wallace AM, Gosek K, Lowe GD, Zukowska-Szczechowska E, Grzeszczak W, Sattar N., Dominiczak AF. Strikingly low circulating CRP concentrations in ultramarathon runners independent of markers of adiposity: how low can you go?. Arteriosclerosis Thrombosis and Vascular Biology 2003; 23: 1640–1644
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. Journal of the American College of Cardiology 2006; 47: C19–C31
   Google Scholar
• Yeh ET, Khan BV. The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. Journal of Thrombosis and Haemostasis 2006; 4: 2308–2316
   PubMedGoogle Scholar